BioLineRx Ltd.
BLRX
$3.10
$0.186.16%
Weiss Ratings | BLRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Very Weak | |||
Risk Grade | E+ | |||
Reward Grade | E | |||
Rating Factors | BLRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Weak | |||
Efficiency Index | Very Weak | |||
Solvency Index | Good | |||
Total Return Index | Very Weak | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | BLRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 1.45 | |||
Price History | BLRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -9.36% | |||
30-Day Total Return | -19.69% | |||
60-Day Total Return | -71.69% | |||
90-Day Total Return | -85.55% | |||
Year to Date Total Return | -69.68% | |||
1-Year Total Return | -90.66% | |||
2-Year Total Return | -91.95% | |||
3-Year Total Return | -95.67% | |||
5-Year Total Return | -93.85% | |||
52-Week High % Change | -92.15% | |||
52-Week Low % Change | 2.46% | |||
Price | BLRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $37.22 | |||
52-Week Low Price | $2.85 | |||
52-Week Low Price (Date) | Apr 01, 2025 | |||
52-Week High Price (Date) | Apr 02, 2024 | |||
Valuation | BLRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 11.39M | |||
Enterprise Value | 6.97M | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -0.02 | |||
Earnings Per Share Growth | -68.25% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 159.56 | |||
Price/Book (Q) | 411.27 | |||
Enterprise Value/Revenue (TTM) | 0.32 | |||
Price | $3.10 | |||
Enterprise Value/EBITDA (TTM) | -0.27 | |||
Enterprise Value/EBIT | -0.25 | |||
Market Cap Category | Nano Cap | |||
Dividends and Shares | BLRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 1.20B | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | BLRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 972 8 642 9100 | |||
Address | -- | |||
Website | www.biolinerx.com | |||
Country | Israel | |||
Year Founded | 2003 | |||
Profitability | BLRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -126.61% | |||
Profit Margin | -90.57% | |||
Management Effectiveness | BLRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -32.96% | |||
Return on Equity | -- | |||
Income Statement | BLRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 21.99M | |||
Total Revenue (TTM) | 21.99M | |||
Revenue Per Share | $0.02 | |||
Gross Profit (TTM) | 15.13M | |||
EBITDA (TTM) | -25.49M | |||
EBIT (TTM) | -27.85M | |||
Net Income (TTM) | -19.92M | |||
Net Income Avl. to Common (TTM) | -19.92M | |||
Total Revenue Growth (Q YOY) | -- | |||
Earnings Growth (Q YOY) | 63.66% | |||
EPS Diluted (TTM) | -0.02 | |||
EPS Diluted Growth (Q YOY) | 71.51% | |||
Balance Sheet | BLRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 29.17M | |||
Cash Per Share (Q) | $0.02 | |||
Total Current Assets (Q) | 37.85M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 8.51M | |||
Current Ratio (Q) | 1.516 | |||
Book Value Per Share (Q) | $0.01 | |||
Total Assets (Q) | 52.74M | |||
Total Current Liabilities (Q) | 24.96M | |||
Total Debt (Q) | 29.61M | |||
Total Liabilities (Q) | 44.24M | |||
Total Common Equity (Q) | 8.51M | |||
Cash Flow | BLRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -2.18M | |||
Cash from Financing (TTM) | 33.51M | |||
Net Change in Cash (TTM) | 1.11M | |||
Levered Free Cash Flow (TTM) | -18.34M | |||
Cash from Operations (TTM) | -30.27M | |||